三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
预计到2024年中国EGFRex20insNSCLC新发患者数量将达到3.5万
预计到2024年中国EGFRex20insNSCLC新发患者数量将达到3.5万
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:335KB
图片尺寸:2268*1049
同报告图片
/
4
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
所属报告:
创新药疾病行业专题报告:EGFR ex20ins NSCLC处于突破的前夜布局正当时-231115(57页).pdf
打包全文图表
相关数据
中国EGFRex20insNSCLC新发患者数量
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
收藏
行业数据
2025-06-23
原图定位
查看详情
全球EGFRex20insNSCLC新发患者数量
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
收藏
行业数据
2025-06-23
原图定位
查看详情
舒沃替尼二线治疗EGFRex20insNSCLC具有“Best-in-class”竞争力
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
收藏
行业数据
2023-11-17
原图定位
查看详情
埃万妥单抗联合化疗一线治疗EGFRex20insNSCLC的全球三期PAPILLON临
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
收藏
行业数据
2023-11-17
原图定位
查看详情
预计到2024年全球EGFRex20insNSCLC新发患者数量将达到7.4万
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
收藏
行业数据
2023-11-17
原图定位
查看详情
CLN-081针对一例对EGFRex20insNSCLC基线有CNS靶病灶的患者观察到颅
fCDpobnnm64gICAgICAgfCDmlbDmja4gICAgIHwKfC0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tfAp8IEJhc2VsaW5lICAgfCAxOSBtbSAgICB8CnwgQ3ljbGUgNiAgICB8IDEwIG1tICAgIHwKCgrotYTmlpnmnaXmupDvvJpKb3VybmFsIG9mIENsaW5pY2FsIE9uY29sb2d5IChET0k6MTAuMTIwMC9KQ08uMjMuMDAxNTIp77yM5Lic5YyX6K+B5Yi4
收藏
行业数据
2023-11-17
原图定位
查看详情
CLN-081启动EGFRex20insNSCLC一线治疗临床试验
fCBTdHVkeSBEZXRhaWxzIHwgVGFidWxhciBWaWV3IHwgTm8gUmVzdWx0cyBQb3N0ZWQgfCBEaXNjbGFpbWVyIHwgSG93IHRvIFJlYWQgYSBTdHVkeSBSZWNvcmQgfAp8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8CnwgKipDb25kaXRpb24gb3IgZGlzZWFzZSoqIHwgKipJbnRlcnZlbnRpb24vdHJlYXRtZW50KiogfCAqKlBoYXNlKiogfCAgfCAgfAp8IEFkdmFuY2VkIG9yIE1ldGFzdGF0aWMgTlNDTEMgV2l0aCBFeG9uIDIwIEluc2VydGlvbiBNdXRhdGlvbiB8IERydWc6IFRBUzY0MTcgfCBQaGFzZSAzIHwgIHw=
收藏
行业数据
2023-11-17
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
EGFR 基因位于人 7 号染色体 p12-q22 区,包括 28 个外显子和 27 个内含子,它的激活突变通常出现在 EGFR 酪氨酸激酶结构域的前 4 个外显子(外显子 18、19、20 和 21)。EGFR 最常见的突变亚型是 19 号外显子的缺失(EGFRex19del)和21 号外显子的 L858R 点突变,二者被认为是 EGFR 敏感突变类型,占据了 EGFR基因突变非小细胞肺癌患者的 85%。20 号外显子插入突变(EGFR ex20ins)主要是以碱基 3 倍数插入或重复的整码突变方式加入到 20 号外显子中,造成编码蛋白的构象改变,从而使 EGFR 蛋白不依赖细胞生长因子信号,导致胞内酪氨酸激酶自动磷酸化,促进肿瘤细胞的增殖,抑制肿瘤细胞凋亡,这种突变是 EGFR 非经典突变中最常见的类型,在 NSCLC EGFR 突变中的比例仅次于两种经典突变,约占 12%,在 NSCLC 中的发生率为 1%-3%,与 RET 和 ROS1 的突变频率相似,在腺癌、女性、从不吸烟和亚洲患者中更为常见,这一点类似于 EGFR 经典突变,临床特征也与 EGFR 经典突变类似。NSCLC 作为全球最高发的癌症之一,患者基数庞大,EGFR ex20ins 突变 NSCLC 人群数量不容小觑。据弗若斯特沙利文的测算,2019 年全球EGFR ex20ins 突变 NSCLC 新发患者数量为 6.4 万,预计到 2024 年将达到 7.4 万,2030 年将达 8.6 万。中国肺癌新发患者数量同样呈稳步增长趋势,2019 年中国 EGFR ex20ins 突变 NSCLC 新发患者数量为 3.0 万,预计到 2024 年将达到 3.5 万,2030 年将达 4.2 万。
行业数据
原图定位
当前图表所属:
创新药疾病行业专题报告:EGFR ex20ins NSCLC处于突破的前夜布局正当时-231115(57页).pdf
EGFRex20insNSCLC一线治疗指南尚无有效疗法推荐
不同突变亚型的EGFRex20ins对不同治疗药物的IC50值
特殊的空间结构致使EGFRex20insNSCLC药物开发难度较大
EGFRPROTAC全球竞争格局
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》